IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review
International Journal of Molecular Sciences · 22.07.2026 · 27 (14) · 6496
DOI: 10.3390/ijms27146496 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.07.2026. Verfasst von Justyna Kunikowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Adult Psychiatry, Medical University of Lodz, 91-229 Lodz, Poland. Hauptthemen laut MEDLINE: Interleukin-1, Anxiety Disorders, Depressive Disorder, Neuroimmunomodulation. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Department of Adult Psychiatry.
Abstract (Originalsprache)
Neuroimmune dysregulation and altered pro- and anti-inflammatory signaling have been implicated in selected phenotypes of depressive and anxiety disorders. Interleukin-37 (IL-37), a member of the IL-1 family, exerts anti-inflammatory effects through extracellular signaling involving IL-18Rα and IL-1R8 and intracellular interactions with SMAD3. This scoping review mapped direct and indirect evidence concerning the relevance of IL-37 to depressive and anxiety disorders. PubMed/MEDLINE was searched through 12 July 2026, supplemented by backward citation searching and reference-list checking; evidence was charted by study type, population or model, IL-37 assessment, principal findings, and level of psychiatric relevance. Thirty-two IL-37-related sources were included. Direct psychiatric evidence comprised one small cross-sectional human study and two rodent stress-model studies, in which IL-37 was assessed as one component of broader inflammatory profiles rather than as a prespecified primary biomarker or intervention target. The remaining evidence was derived from non-psychiatric inflammatory conditions, central nervous system disease models, or mechanistic studies. These findings provide hypothesis-generating biological context but do not establish psychiatric specificity, causality, biomarker validity, or therapeutic efficacy. IL-37 should therefore be considered an exploratory research variable requiring validation in well-characterized longitudinal psychiatric cohorts using standardized assays and integrated immune profiling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Adult Psychiatry, Medical University of Lodz, 91-229 Lodz, Poland.
- College of Medicine, China Medical University (CMU), Taichung 404333, Taiwan.
- Mind-Body Interface Research Center (MBI Lab & Care), CMU Hospital, Taichung 40447, Taiwan.
- Office of Research and Development, Asia University, Taichung 413305, Taiwan.
- An-Nan Hospital, China Medical University (CMU), Tainan 709204, Taiwan.
- Department of Psychotherapy, Medical University of Lodz, 91-229 Lodz, Poland.
ORCID-Profile: Justyna Kunikowska, Piotr Gałecki, Kuan Pin Su, Katarzyna Bliźniewska-Kowalska, Małgorzata Gałecka
Förderung
- Medical University of Lodz
- Department of Adult Psychiatry
Zitieren
APA
Kunikowska, J., Gałecki, P., Su, K. P., Bliźniewska-Kowalska, K., & Gałecka, M. (2026). IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review. International Journal of Molecular Sciences, 27(14), 6496. https://doi.org/10.3390/ijms27146496
Vancouver
Kunikowska J, Gałecki P, Su KP, Bliźniewska-Kowalska K, Gałecka M. IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review. International Journal of Molecular Sciences. 2026;27(14):6496. doi:10.3390/ijms27146496
BibTeX
@article{Kunikowska2026,
author = {Kunikowska, Justyna and Gałecki, Piotr and Su, Kuan Pin and Bliźniewska-Kowalska, Katarzyna and Gałecka, Małgorzata},
title = {IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6496},
doi = {10.3390/ijms27146496}
}
EUVIMED